APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nintedanib Generics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nintedanib Generics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174017130327 December 2025189 pages

Choose your research edition.

Industry ResearchNintedanib Generics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Nintedanib Generics Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Nintedanib Generics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nintedanib Generics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Nintedanib Generics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Nintedanib Generics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nintedanib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nintedanib Generics include CSPC Pharmaceutical Group, PuraCap, Qilu Pharmaceutical, Kelun Pharmaceutical, Jiangsu Wangao Pharmaceutical, Glenmark, Eskayef Pharmaceuticals, Cipla and Beacon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nintedanib Generics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nintedanib Generics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nintedanib Generics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nintedanib Generics market size, projected growth trends, production technologies, key applications, and end-use industries.

Nintedanib Generics Segment by Company

CSPC Pharmaceutical Group

PuraCap

Qilu Pharmaceutical

Kelun Pharmaceutical

Jiangsu Wangao Pharmaceutical

Glenmark

Eskayef Pharmaceuticals

Cipla

Beacon Pharma

Nintedanib Generics Segment by Type

100mg per Unit

150mg per Unit

Nintedanib Generics Segment by Application

Non-small Cell Lung Cancer

Idiopathic Pulmonary Fibrosis

Other

Nintedanib Generics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nintedanib Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nintedanib Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nintedanib Generics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nintedanib Generics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nintedanib Generics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Nintedanib Generics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Nintedanib Generics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Nintedanib Generics Industry Trends Table 2. Nintedanib Generics Industry Drivers Table 3. Nintedanib Generics Industry Opportunities and Challenges Table 4. Nintedanib Generics Industry Restraints Table 5. Global Nintedanib Generics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Nintedanib Generics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Nintedanib Generics Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Nintedanib Generics Sales Market Share by Manufacturers Table 9. Global Nintedanib Generics Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Nintedanib Generics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Nintedanib Generics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Nintedanib Generics Manufacturers, Product Type & Application Table 13. Global Nintedanib Generics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Nintedanib Generics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 100mg per Unit Table 17. Major Manufacturers of 150mg per Unit Table 18. Global Nintedanib Generics Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Nintedanib Generics Sales by Type (2021-2026) & (K Units) Table 20. Global Nintedanib Generics Sales by Type (2027-2032) & (K Units) Table 21. Global Nintedanib Generics Sales Market Share by Type (2021-2026) Table 22. Global Nintedanib Generics Sales Market Share by Type (2027-2032) Table 23. Global Nintedanib Generics Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Nintedanib Generics Revenue by Type (2021-2026) & (K Units) Table 25. Global Nintedanib Generics Revenue by Type (2027-2032) & (K Units) Table 26. Global Nintedanib Generics Revenue Market Share by Type (2021-2026) Table 27. Global Nintedanib Generics Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Non-small Cell Lung Cancer Table 29. Major Manufacturers of Idiopathic Pulmonary Fibrosis Table 30. Major Manufacturers of Other Table 31. Global Nintedanib Generics Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Nintedanib Generics Sales by Application (2021-2026) & (K Units) Table 33. Global Nintedanib Generics Sales by Application (2027-2032) & (K Units) Table 34. Global Nintedanib Generics Sales Market Share by Application (2021-2026) Table 35. Global Nintedanib Generics Sales Market Share by Application (2027-2032) Table 36. Global Nintedanib Generics Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Nintedanib Generics Revenue by Application (2021-2026) & (K Units) Table 38. Global Nintedanib Generics Revenue by Application (2027-2032) & (K Units) Table 39. Global Nintedanib Generics Revenue Market Share by Application (2021-2026) Table 40. Global Nintedanib Generics Revenue Market Share by Application (2027-2032) Table 41. Global Nintedanib Generics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Nintedanib Generics Sales by Region (2021-2026) & (K Units) Table 43. Global Nintedanib Generics Sales Market Share by Region (2021-2026) Table 44. Global Nintedanib Generics Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Nintedanib Generics Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 48. North America Nintedanib Generics Sales by Country (2027-2032) & (K Units) Table 49. Europe Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 51. Europe Nintedanib Generics Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Nintedanib Generics Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Nintedanib Generics Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Nintedanib Generics Sales by Country (2027-2032) & (K Units) Table 58. Global Nintedanib Generics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Nintedanib Generics Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Nintedanib Generics Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Nintedanib Generics Revenue Market Share by Region (2021-2026) Table 62. Global Nintedanib Generics Revenue Market Share by Region (2027-2032) Table 63. CSPC Pharmaceutical Group Company Information Table 64. CSPC Pharmaceutical Group Business Overview Table 65. CSPC Pharmaceutical Group Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. CSPC Pharmaceutical Group Nintedanib Generics Product Portfolio Table 67. CSPC Pharmaceutical Group Recent Development Table 68. PuraCap Company Information Table 69. PuraCap Business Overview Table 70. PuraCap Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. PuraCap Nintedanib Generics Product Portfolio Table 72. PuraCap Recent Development Table 73. Qilu Pharmaceutical Company Information Table 74. Qilu Pharmaceutical Business Overview Table 75. Qilu Pharmaceutical Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Qilu Pharmaceutical Nintedanib Generics Product Portfolio Table 77. Qilu Pharmaceutical Recent Development Table 78. Kelun Pharmaceutical Company Information Table 79. Kelun Pharmaceutical Business Overview Table 80. Kelun Pharmaceutical Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Kelun Pharmaceutical Nintedanib Generics Product Portfolio Table 82. Kelun Pharmaceutical Recent Development Table 83. Jiangsu Wangao Pharmaceutical Company Information Table 84. Jiangsu Wangao Pharmaceutical Business Overview Table 85. Jiangsu Wangao Pharmaceutical Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Jiangsu Wangao Pharmaceutical Nintedanib Generics Product Portfolio Table 87. Jiangsu Wangao Pharmaceutical Recent Development Table 88. Glenmark Company Information Table 89. Glenmark Business Overview Table 90. Glenmark Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Glenmark Nintedanib Generics Product Portfolio Table 92. Glenmark Recent Development Table 93. Eskayef Pharmaceuticals Company Information Table 94. Eskayef Pharmaceuticals Business Overview Table 95. Eskayef Pharmaceuticals Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Eskayef Pharmaceuticals Nintedanib Generics Product Portfolio Table 97. Eskayef Pharmaceuticals Recent Development Table 98. Cipla Company Information Table 99. Cipla Business Overview Table 100. Cipla Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Cipla Nintedanib Generics Product Portfolio Table 102. Cipla Recent Development Table 103. Beacon Pharma Company Information Table 104. Beacon Pharma Business Overview Table 105. Beacon Pharma Nintedanib Generics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Beacon Pharma Nintedanib Generics Product Portfolio Table 107. Beacon Pharma Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Nintedanib Generics Distributors List Table 111. Nintedanib Generics Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Nintedanib Generics Product Image Figure 2. Global Nintedanib Generics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nintedanib Generics Market Size (2021-2032) & (US$ Million) Figure 4. Global Nintedanib Generics Sales (2021-2032) & (K Units) Figure 5. Global Nintedanib Generics Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Nintedanib Generics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 100mg per Unit Image Figure 9. 150mg per Unit Image Figure 10. Global Nintedanib Generics Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Nintedanib Generics Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Nintedanib Generics Sales Market Share by Type (2021-2032) Figure 13. Global Nintedanib Generics Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Nintedanib Generics Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Nintedanib Generics Revenue Market Share by Type (2021-2032) Figure 16. Non-small Cell Lung Cancer Image Figure 17. Idiopathic Pulmonary Fibrosis Image Figure 18. Other Image Figure 19. Global Nintedanib Generics Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Nintedanib Generics Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nintedanib Generics Sales Market Share by Application (2021-2032) Figure 22. Global Nintedanib Generics Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Nintedanib Generics Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Nintedanib Generics Revenue Market Share by Application (2021-2032) Figure 25. North America Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Nintedanib Generics Sales Market Share by Country (2021-2032) Figure 27. U.S. Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Nintedanib Generics Sales Market Share by Country (2021-2032) Figure 32. Germany Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Nintedanib Generics Sales Market Share by Country (2021-2032) Figure 39. China Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Nintedanib Generics Sales Market Share by Country (2021-2032) Figure 47. Brazil Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Nintedanib Generics Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Nintedanib Generics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Nintedanib Generics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Nintedanib Generics Revenue (2021-2032) & (US$ Million) Figure 58. North America Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Nintedanib Generics Revenue (2021-2032) & (US$ Million) Figure 60. Europe Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Nintedanib Generics Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Nintedanib Generics Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Nintedanib Generics Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Nintedanib Generics Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg per Unit
  • 150mg per Unit
Applications
  • Non-small Cell Lung Cancer
  • Idiopathic Pulmonary Fibrosis
  • Other
Companies covered
  • CSPC Pharmaceutical Group
  • PuraCap
  • Qilu Pharmaceutical
  • Kelun Pharmaceutical
  • Jiangsu Wangao Pharmaceutical
  • Glenmark
  • Eskayef Pharmaceuticals
  • Cipla
  • Beacon Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nintedanib Generics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nintedanib Generics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Nintedanib Generics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Nintedanib Generics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Nintedanib Generics Market Dynamics
  1. 2.1 Nintedanib Generics Industry Trends
  2. 2.2 Nintedanib Generics Industry Drivers
  3. 2.3 Nintedanib Generics Industry Opportunities and Challenges
  4. 2.4 Nintedanib Generics Industry Restraints
3 Nintedanib Generics Market by Manufacturers
  1. 3.1 Global Nintedanib Generics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Nintedanib Generics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Nintedanib Generics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Nintedanib Generics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nintedanib Generics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Nintedanib Generics Manufacturers, Product Type & Application
  7. 3.7 Global Nintedanib Generics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nintedanib Generics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nintedanib Generics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nintedanib Generics Tier 1, Tier 2, and Tier 3
4 Nintedanib Generics Market by Type
  1. 4.1 Nintedanib Generics Type Introduction
  2. 4.1.1 100mg per Unit
  3. 4.1.2 150mg per Unit
  4. 4.2 Global Nintedanib Generics Sales by Type
  5. 4.2.1 Global Nintedanib Generics Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nintedanib Generics Sales by Type (2021-2032)
  7. 4.2.3 Global Nintedanib Generics Sales Market Share by Type (2021-2032)
  8. 4.3 Global Nintedanib Generics Revenue by Type
  9. 4.3.1 Global Nintedanib Generics Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Nintedanib Generics Revenue by Type (2021-2032)
  11. 4.3.3 Global Nintedanib Generics Revenue Market Share by Type (2021-2032)
5 Nintedanib Generics Market by Application
  1. 5.1 Nintedanib Generics Application Introduction
  2. 5.1.1 Non-small Cell Lung Cancer
  3. 5.1.2 Idiopathic Pulmonary Fibrosis
  4. 5.1.3 Other
  5. 5.2 Global Nintedanib Generics Sales by Application
  6. 5.2.1 Global Nintedanib Generics Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nintedanib Generics Sales by Application (2021-2032)
  8. 5.2.3 Global Nintedanib Generics Sales Market Share by Application (2021-2032)
  9. 5.3 Global Nintedanib Generics Revenue by Application
  10. 5.3.1 Global Nintedanib Generics Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nintedanib Generics Revenue by Application (2021-2032)
  12. 5.3.3 Global Nintedanib Generics Revenue Market Share by Application (2021-2032)
6 Global Nintedanib Generics Sales by Region
  1. 6.1 Global Nintedanib Generics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nintedanib Generics Sales by Region (2021-2032)
  3. 6.2.1 Global Nintedanib Generics Sales by Region (2021-2026)
  4. 6.2.2 Global Nintedanib Generics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Nintedanib Generics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Nintedanib Generics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Nintedanib Generics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Nintedanib Generics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Nintedanib Generics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Nintedanib Generics Revenue by Region
  1. 7.1 Global Nintedanib Generics Revenue by Region
  2. 7.1.1 Global Nintedanib Generics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Nintedanib Generics Revenue by Region (2021-2026)
  4. 7.1.3 Global Nintedanib Generics Revenue by Region (2027-2032)
  5. 7.1.4 Global Nintedanib Generics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Nintedanib Generics Revenue (2021-2032)
  8. 7.2.2 North America Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Nintedanib Generics Revenue (2021-2032)
  11. 7.3.2 Europe Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Nintedanib Generics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Nintedanib Generics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Nintedanib Generics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSPC Pharmaceutical Group
  2. 8.1.1 CSPC Pharmaceutical Group Company Information
  3. 8.1.2 CSPC Pharmaceutical Group Business Overview
  4. 8.1.3 CSPC Pharmaceutical Group Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSPC Pharmaceutical Group Nintedanib Generics Product Portfolio
  6. 8.1.5 CSPC Pharmaceutical Group Recent Developments
  7. 8.2 PuraCap
  8. 8.2.1 PuraCap Company Information
  9. 8.2.2 PuraCap Business Overview
  10. 8.2.3 PuraCap Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 PuraCap Nintedanib Generics Product Portfolio
  12. 8.2.5 PuraCap Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Nintedanib Generics Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Kelun Pharmaceutical
  20. 8.4.1 Kelun Pharmaceutical Company Information
  21. 8.4.2 Kelun Pharmaceutical Business Overview
  22. 8.4.3 Kelun Pharmaceutical Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kelun Pharmaceutical Nintedanib Generics Product Portfolio
  24. 8.4.5 Kelun Pharmaceutical Recent Developments
  25. 8.5 Jiangsu Wangao Pharmaceutical
  26. 8.5.1 Jiangsu Wangao Pharmaceutical Company Information
  27. 8.5.2 Jiangsu Wangao Pharmaceutical Business Overview
  28. 8.5.3 Jiangsu Wangao Pharmaceutical Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Wangao Pharmaceutical Nintedanib Generics Product Portfolio
  30. 8.5.5 Jiangsu Wangao Pharmaceutical Recent Developments
  31. 8.6 Glenmark
  32. 8.6.1 Glenmark Company Information
  33. 8.6.2 Glenmark Business Overview
  34. 8.6.3 Glenmark Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Glenmark Nintedanib Generics Product Portfolio
  36. 8.6.5 Glenmark Recent Developments
  37. 8.7 Eskayef Pharmaceuticals
  38. 8.7.1 Eskayef Pharmaceuticals Company Information
  39. 8.7.2 Eskayef Pharmaceuticals Business Overview
  40. 8.7.3 Eskayef Pharmaceuticals Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eskayef Pharmaceuticals Nintedanib Generics Product Portfolio
  42. 8.7.5 Eskayef Pharmaceuticals Recent Developments
  43. 8.8 Cipla
  44. 8.8.1 Cipla Company Information
  45. 8.8.2 Cipla Business Overview
  46. 8.8.3 Cipla Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cipla Nintedanib Generics Product Portfolio
  48. 8.8.5 Cipla Recent Developments
  49. 8.9 Beacon Pharma
  50. 8.9.1 Beacon Pharma Company Information
  51. 8.9.2 Beacon Pharma Business Overview
  52. 8.9.3 Beacon Pharma Nintedanib Generics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Beacon Pharma Nintedanib Generics Product Portfolio
  54. 8.9.5 Beacon Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nintedanib Generics Value Chain Analysis
  2. 9.1.1 Nintedanib Generics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nintedanib Generics Production Mode & Process
  6. 9.2 Nintedanib Generics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nintedanib Generics Distributors
  9. 9.2.3 Nintedanib Generics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst